Tivozanib is a recently developed, small-molecule tyrosine kinase inhibitor with specific affinity for the vascular endothelial growth factor receptor (VEGFR) family of kinases.
Given known relevance of VHL (Von Hippel-Lindau disease tumor suppressor) deregulation in the clear cell variant of renal cell carcinoma, renal cell carcinoma remains an area of interest and subject of recent registration trials with this approach. TIVO-1, a phase III study evaluating tivozanib versus sorafenib in the first-line setting, met its primary endpoint of progression-free survival (11.9 months for tivozanib vs. 9.1 months for sorafenib), with a manageable toxicity profile, leading to formal consideration of regulatory approval in this setting. This review focuses on the preclinical development, pharmacokinetics and early clinical activity of tivozanib in renal cell carcinoma and other solid tumors.
Written by:
Berge EM, Bowles DW, Flaig TW, Lam ET, Jimeno A. Are you the author?
University of Colorado School of Medicine, Denver, CO, USA.
Reference: Drugs Today (Barc). 2013 May;49(5):303-15.
doi: 10.1358/dot.2013.49.5.1960218
PubMed Abstract
PMID: 23724410
UroToday.com Renal Cancer Section
